{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T15:01:04Z","timestamp":1777561264700,"version":"3.51.4"},"reference-count":47,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2013,1,1]],"date-time":"2013-01-01T00:00:00Z","timestamp":1356998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2013,1]]},"DOI":"10.1016\/j.leukres.2012.09.012","type":"journal-article","created":{"date-parts":[[2012,10,10]],"date-time":"2012-10-10T16:40:34Z","timestamp":1349887234000},"page":"43-49","source":"Crossref","is-referenced-by-count":16,"title":["Emerging kinetics of BCR\u2013ABL1 mutations and their effect on disease outcomes in chronic myeloid leukemia patients with imatinib failure"],"prefix":"10.1016","volume":"37","author":[{"given":"Lee-Yung","family":"Shih","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming-Chung","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ching-Yuan","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tseng-Hsi","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li-Yaun","family":"Bai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsai-Yun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming-Chung","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tung-Liang","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yii-Jenq","family":"Lan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chih-Cheng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Youngsen","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pei-Ching","family":"Hsiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chang-Liang","family":"Lai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chia-Hui","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tung-Huei","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2012.09.012_bib0005","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1056\/NEJM199907153410306","article-title":"The biology of chronic myeloid leukemia","volume":"341","author":"Faderl","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2012.09.012_bib0010","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1126\/science.289.5486.1938","article-title":"Structural mechanism for STI-571 inhibition of Abelson tyrosine kinase","volume":"289","author":"Schindler","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.leukres.2012.09.012_bib0015","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nm0596-561","article-title":"Effects of a selective inhibitor of the ABL tyrosine kinase on the growth of BCR\u2013ABL positive cells","volume":"2","author":"Druker","year":"1996","journal-title":"Nat Med"},{"key":"10.1016\/j.leukres.2012.09.012_bib0020","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2012.09.012_bib0025","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1182\/blood-2006-02-005686","article-title":"Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet","volume":"108","author":"Baccarani","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2012.09.012_bib0030","doi-asserted-by":"crossref","first-page":"3530","DOI":"10.1182\/blood.V99.10.3530","article-title":"Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study","volume":"99","author":"Sawyers","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2012.09.012_bib0035","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1126\/science.1062538","article-title":"Clinical resistance to STI-571 cancer therapy caused by BCR\u2013ABL gene mutation or amplification","volume":"293","author":"Gorre","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.leukres.2012.09.012_bib0040","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/S0092-8674(03)00190-9","article-title":"Mechanisms of autoinhibition and STI-571\/imatinib resistance revealed by mutagenesis of BCR\u2013ABL","volume":"112","author":"Azam","year":"2003","journal-title":"Cell"},{"key":"10.1016\/j.leukres.2012.09.012_bib0045","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1535-6108(02)00096-X","article-title":"Multiple BCR\u2013ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia","volume":"2","author":"Shah","year":"2002","journal-title":"Cancer Cell"},{"key":"10.1016\/j.leukres.2012.09.012_bib0050","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1182\/blood.V99.9.3472","article-title":"High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR\/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance","volume":"99","author":"Branford","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2012.09.012_bib0055","doi-asserted-by":"crossref","first-page":"7374","DOI":"10.1158\/1078-0432.CCR-06-1516","article-title":"Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia","volume":"12","author":"Soverini","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.leukres.2012.09.012_bib0060","doi-asserted-by":"crossref","first-page":"186","DOI":"10.3324\/haematol.11993","article-title":"Dynamics of BCR\u2013ABL mutated clones prior to hematologic or cytogenetic resistance to imatinib","volume":"93","author":"Ernst","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2012.09.012_bib0065","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1182\/blood.V100.3.1014","article-title":"Several types of mutations of the ABL gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment","volume":"100","author":"Roche-Lestienne","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2012.09.012_bib0070","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1182\/blood-2005-03-1036","article-title":"High-sensitivity detection of BCR\u2013ABL kinase domain mutations in imatinib-na\u00efve patients: correlation with clonal cytogenetic evolution but not response to therapy","volume":"106","author":"Willis","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2012.09.012_bib0075","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1182\/blood-2002-09-2896","article-title":"Detection of BCR\u2013ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate \u2013binding loop (P-loop) are associated with a poor prognosis","volume":"102","author":"Branford","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2012.09.012_bib0080","doi-asserted-by":"crossref","first-page":"4100","DOI":"10.1200\/JCO.2005.05.531","volume":"23","author":"Soverini","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2012.09.012_bib0085","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1038\/sj.leu.2404318","article-title":"Frequency and clinical significance of BCR\u2013ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate","volume":"20","author":"Jabbour","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2012.09.012_bib0090","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1038\/sj.leu.2404137","article-title":"The presence of a BCR\u2013ABL mutant allele in CML does not always explain clinical resistance to imatinib","volume":"20","author":"Khorashad","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2012.09.012_bib0095","doi-asserted-by":"crossref","first-page":"4611","DOI":"10.1182\/blood-2002-12-3659","article-title":"Several BCR\u2013ABL kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib","volume":"101","author":"Corbin","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2012.09.012_bib0100","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/sj.leu.2404554","article-title":"Mutations of the BCR\u2013ABL-kinase domain occur in a minority of patients with stable complete cytogenetic response to imatinib","volume":"21","author":"Sherbenou","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2012.09.012_bib0105","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.ejca.2011.08.015","article-title":"Quantitative monitoring of BCR\/ABL1 mutants for surveillance of subclone-evolution-expansion, and -depletion in chronic myeloid leukaemia","volume":"48","author":"Preuner","year":"2012","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.leukres.2012.09.012_bib0110","doi-asserted-by":"crossref","first-page":"7519","DOI":"10.1158\/1078-0432.CCR-09-1068","article-title":"Mechanisms of resistance to imatinib and second-generation tyrosine inhibitors in chronic myeloid leukemia","volume":"15","author":"Milojkovic","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.leukres.2012.09.012_bib0115","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1038\/sj.leu.2404236","article-title":"Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients: a retrospective analysis from the French intergroup of CML (Fi(phi)-LMC GROUP)","volume":"20","author":"Nicolini","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2012.09.012_bib0120","doi-asserted-by":"crossref","first-page":"4806","DOI":"10.1200\/JCO.2008.16.9953","article-title":"Finding of kinase domain mutations in patients with chronic phase chronic myeloid leukemia responding to imatinib may identify those at high risk of disease progression","volume":"26","author":"Khorashad","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2012.09.012_bib0125","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/blood-2006-01-0092","article-title":"Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR\u2013ABL transcripts and kinase domain mutations and for expressing results","volume":"108","author":"Hughes","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2012.09.012_bib0130","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1002\/cncr.25717","article-title":"Practical advice for determining the role of BCR\u2013ABL mutations in guiding tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia","volume":"117","author":"Jabbour","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2012.09.012_bib0135","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa055229","article-title":"Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias","volume":"354","author":"Talpaz","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2012.09.012_bib0140","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1182\/blood-2007-03-080689","article-title":"Nilotinib (formerly AMN107), a highly selective BCR\u2013ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance","volume":"110","author":"Kantarjian","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2012.09.012_bib0145","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1158\/0008-5472.CAN-05-0259","article-title":"In vitro activity of BCR\u2013ABL inhibitors AMN107 and BMS-54825 against clinically relevant imatinib-resistant ABL kinase domain mutants","volume":"65","author":"O\u2019Hare","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.leukres.2012.09.012_bib0150","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1038\/sj.leu.2403307","article-title":"Detection of ABL kinase domain mutations with denaturing high-performance liquid chromatography","volume":"18","author":"Deininger","year":"2004","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2012.09.012_bib0155","doi-asserted-by":"crossref","first-page":"4005","DOI":"10.1182\/blood-2007-03-080838","article-title":"Dynamics of BCR\u2013ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors","volume":"110","author":"Cortes","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2012.09.012_bib0160","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1182\/blood-2007-06-096396","article-title":"In vivo kinetics of kinase domain mutations in CML patients treated with dasatinib after failing imatinib","volume":"111","author":"Khorashad","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2012.09.012_bib0165","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1038\/sj.leu.2401592","article-title":"Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease","volume":"13","author":"van Dongen","year":"1999","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2012.09.012_bib0170","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1038\/sj.leu.2403135","article-title":"Standardization and quality control studies of \u2018real-time\u2019 quantitative reverse transcriptase polymerase chain reaction (RQ-PCR) of fusion gene transcripts for residual disease detection in leukemia \u2013 A Europe Against Cancer Program","volume":"17","author":"Gabert","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2012.09.012_bib0175","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1038\/sj.leu.2403136","article-title":"Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using \u2018real-time\u2019 quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) \u2013 A Europe Against Cancer Program","volume":"17","author":"Beillard","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2012.09.012_bib0180","doi-asserted-by":"crossref","first-page":"221a","DOI":"10.1182\/blood.V108.11.737.737","article-title":"First results from a collaborative initiative to develop an international scale for the measurement of BCR\u2013ABL by RQ-PCR based on deriving laboratory-specific conversion factors","volume":"108","author":"Branford","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2012.09.012_bib0185","doi-asserted-by":"crossref","first-page":"3330","DOI":"10.1182\/blood-2008-04-150680","article-title":"Desirable performance characteristics for BCR\u2013ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials","volume":"112","author":"Branford","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2012.09.012_bib0190","series-title":"Myeloid leukemia","first-page":"p. 93","article-title":"Detection of BCR\u2013ABL mutations and resistance to imatinib mesylate","volume":"vol. 125","author":"Branford","year":"2006"},{"key":"10.1016\/j.leukres.2012.09.012_bib0195","doi-asserted-by":"crossref","first-page":"111","DOI":"10.3121\/cmr.1.2.111","article-title":"Use of GC clamps in DHPLC mutation scanning","volume":"1","author":"Wurzburger","year":"2003","journal-title":"Clin Med Res"},{"key":"10.1016\/j.leukres.2012.09.012_bib0200","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1101\/gr.11.1.3","article-title":"Pyrosequencing sheds light on DNA sequencing","volume":"11","author":"Ronaghi","year":"2001","journal-title":"Genome Res"},{"key":"10.1016\/j.leukres.2012.09.012_bib0205","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1182\/blood-2008-08-173674","article-title":"Determining the rise in BCR\u2013ABL RNA that optimally predicts a kinase doma in mutation in patients with chronic myeloid leukemia on imatinib","volume":"114","author":"Press","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2012.09.012_bib0210","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.3109\/10428191003729741","article-title":"Mutations in ABL kinase doma in are associated with inferior progression-free survival","volume":"51","author":"Sharma","year":"2010","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.leukres.2012.09.012_bib0215","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/S1470-2045(07)70342-X","article-title":"Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia","volume":"8","author":"Apperley","year":"2007","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.leukres.2012.09.012_bib0220","doi-asserted-by":"crossref","first-page":"4944","DOI":"10.1182\/blood-2009-04-214221","article-title":"Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR\u2013ABL mutations","volume":"114","author":"Muller","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2012.09.012_bib0225","doi-asserted-by":"crossref","first-page":"4204","DOI":"10.1200\/JCO.2009.21.8230","article-title":"Impact of baseline BCR\u2013ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase","volume":"27","author":"Hughes","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2012.09.012_bib0230","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1182\/blood-2010-12-326405","article-title":"BCR\u2013ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet","volume":"118","author":"Soverini","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2012.09.012_bib0235","doi-asserted-by":"crossref","first-page":"5426","DOI":"10.1182\/blood-2009-08-215939","article-title":"Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR\u2013ABL mutation status really matter?","volume":"114","author":"Branford","year":"2009","journal-title":"Blood"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212612003852?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212612003852?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,7,14]],"date-time":"2020-07-14T17:17:47Z","timestamp":1594747067000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212612003852"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,1]]}},"alternative-id":["S0145212612003852"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2012.09.012","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2013,1]]}}}